Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin

被引:0
作者
Jia, Zhongwei [1 ]
Xia, Jinxing [1 ]
Lu, Qiong [1 ]
机构
[1] Anhui Med Univ, Clin Lab Dept, Affiliated Hosp 1, Hefei, Peoples R China
关键词
orthopedics; serum free light chains; sFLC kappa/lambda ratio; immunofixation electrophoresis; multiple myeloma; total protein; CRITERIA;
D O I
10.1093/labmed/lmad104
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: A substantial number of patients with multiple myeloma (MM) who have bone destruction are initially admitted into the orthopedic service at the hospital. However, routine laboratory testing usually fails to identify these patients, thus delaying optimal therapy. Therefore, there is a clear medical need for early diagnosis of MM in these patients.Methods: Between 2019 and 2021, 42 patients receiving treatment for orthopedic conditions had normal hemoglobin (Hb), total protein (TP), albumin (ALB), creatinine (CREA), and blood calcium (Ca) levels before their surgical procedure(s) but were subsequently pathologically confirmed to have MM, based on their presenting orthopedic symptoms. During the same period, 52 patients with orthopedic conditions were pathologically excluded from the diagnosis of MM and were recruited into our control group. Serum free light chain (sFLC) testing was performed in 94 consecutive patients in the orthopedic service using Siemens N Latex FLC kits. The levels of Hb, TP, ALB, CREA, and Ca were also measured. All 42 patients with MM were divided into group A (n = 25: kappa proliferation) and group B (n = 17: lambda proliferation) by the pathology department.Results: There were no significant differences in levels of Hb, TP, ALB, CREA, and Ca between group A and group B and the control group. However, the sFLC kappa/lambda ratio of group A and B was also significantly different from that of the control group (P < .001). The results of serum immunofixation electrophoresis (IFE) testing demonstrated negative results in 14 cases (58.3%) in group A and 4 cases (25.0%) in group B.Conclusions: Some patients with orthopedic conditions who do not have typical MM laboratory results, such as those with abnormal Hb, TP, ALB, CREA, and Ca levels before their operation(s), actually have MM. MM should be highly suspected in patients with unexplained bone lesions and with an abnormal sFLC kappa/lambda ratio. Further tissue or bone marrow biopsy is needed in these patients even if serum and urine IFE results are negative and light chain ratio is normal.
引用
收藏
页码:454 / 459
页数:6
相关论文
共 19 条
  • [1] Bradwell AR, 2001, CLIN CHEM, V47, P673
  • [2] Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    Dimopoulos, Meletios
    Kyle, Robert
    Fermand, Jean-Paul
    Rajkumar, S. Vincent
    San Miguel, Jesus
    Chanan-Khan, Asher
    Ludwig, Heinz
    Joshua, Douglas
    Mehta, Jayesh
    Gertz, Morie
    Avet-Loiseau, Herve
    Beksac, Meral
    Anderson, Kenneth C.
    Moreau, Philippe
    Singhal, Seema
    Goldschmidt, Hartmut
    Boccadoro, Mario
    Kumar, Shaji
    Giralt, Sergio
    Munshi, Nikhil C.
    Jagannath, Sundar
    [J]. BLOOD, 2011, 117 (18) : 4701 - 4705
  • [3] Emerging Therapies in Multiple Myeloma
    El-Amm, Joelle
    Tabbara, Imad A.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (03): : 315 - 321
  • [4] The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
    Garcia-Ortiz, Almudena
    Rodriguez-Garcia, Yaiza
    Encinas, Jessica
    Maroto-Martin, Elena
    Castellano, Eva
    Teixido, Joaquin
    Martinez-Lopez, Joaquin
    [J]. CANCERS, 2021, 13 (02) : 1 - 22
  • [5] Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment
    Gertz, Morie A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (07) : 848 - 860
  • [6] Emerging biomarkers in Multiple Myeloma: A review
    Gupta, Nidhi
    Sharma, Aparna
    Sharma, Alpana
    [J]. CLINICA CHIMICA ACTA, 2020, 503 : 45 - 53
  • [7] Clinical Comparisons of Two Free Light Chain Assays to Immunofixation Electrophoresis for Detecting Monoclonal Gammopathy
    Kim, Han-Sung
    Kim, Hyun Soo
    Shin, Kyu-Sung
    Song, Wonkeun
    Kim, Hyo Jung
    Kim, Hyeong Su
    Park, Min-Jeong
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [8] International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    Kumar, Shaji
    Paiva, Bruno
    Anderson, Kenneth C.
    Durie, Brian
    Landgren, Ola
    Moreau, Philippe
    Munshi, Nikhil
    Lonial, Sagar
    Blade, Joan
    Mateos, Maria-Victoria
    Dimopoulos, Meletios
    Kastritis, Efstathios
    Boccadoro, Mario
    Orlowski, Robert
    Goldschmidt, Hartmut
    Spencer, Andrew
    Hou, Jian
    Chng, Wee Joo
    Usmani, Saad Z.
    Zamagni, Elena
    Shimizu, Kazuyuki
    Jagannath, Sundar
    Johnsen, Hans E.
    Terpos, Evangelos
    Reiman, Anthony
    Kyle, Robert A.
    Sonneveld, Pieter
    Richardson, Paul G.
    McCarthy, Philip
    Ludwig, Heinz
    Chen, Wenming
    Cavo, Michele
    Harousseau, Jean-Luc
    Lentzsch, Suzanne
    Hillengass, Jens
    Palumbo, Antonio
    Orfao, Alberto
    Rajkumar, S. Vincent
    Miguel, Jesus San
    Avet-Loiseau, Herve
    [J]. LANCET ONCOLOGY, 2016, 17 (08) : E328 - E346
  • [9] Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
    Markovic, Uros
    Romano, Alessandra
    Bellofiore, Claudia
    Condorelli, Annalisa
    Garibaldi, Bruno
    Bulla, Anna
    Duminuco, Andrea
    Del Fabro, Vittorio
    Di Raimondo, Francesco
    Conticello, Concetta
    [J]. CANCERS, 2021, 13 (23)
  • [10] Serum free light chains for monitoring multiple myeloma
    Mead, GP
    Carr-Smith, HD
    Drayson, MT
    Morgan, GJ
    Child, JA
    Bradwell, AR
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (03) : 348 - 354